Analysis on the value of zoledronic acid combined with alfacalcidol in the treatment of postmenopausal osteoporosis based on levels of serum PINP and β-CTX
Objective To analyze the value of zoledronic acid combined with alfacalcidol in the treatment of postmenopausal osteoporosis(PMOP)based on serum procollagen type I N-terminal propeptide(PINP)and β-C-terminal cross-linked telopeptide of type Ⅰ collagen(β-CTX).Meth-ods A total of 500 patients with PMOP treated were enrolled as the research objects from July to December 2023.According to simple random number table method,they were divided into single treatment group(treated with zoledronic acid)and combined treatment group(treated with zoledronic acid combined with alfacalcidol),250 cases in each group.Compare the treatment effects of two groups,including lumbar spine L1～4,femoral neck and femoral trochanter bone density(BMD),and bone metabolism indexes[PINP,β-CTX,osteocalcin(BGP),alkaline phosphatase(ALP)]were compared between the two groups.Results The total effective rate of the combined treatment group was higher than that of single treatment group(98.00%vs.92.40%,P＜0.05).After treatment,the BMD values of lumbar spine L1～4,femoral neck and femoral trochanter in the combined treatment group were greater than those in the single treatment group,and the difference was statistically significant(P＜0.05).After treatment,the levels of serum PINP,β-CTX,BGP and ALP in the combined treatment group were lower than those in single treatment group,and the differences were statistically significant(P＜0.05).The levels of serum PINP,β-CTX and BGP were negatively correlated with BMD at different sites(P＜0.05).Conclusion The combination of zoledronic acid and alfacalcidol has high effect in the treatment of PMOP.The serum PINP and β-CTX are significantly correlated with BMD,which is expected to clinically evaluate the curative effect on PMOP.
NETL
NSTL
万方数据
